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Impact of c-kit mutations, including codons 557 
and/or 558, on the recurrence-free survival after 
curative surgery in patients with GIST
4
Background : Recently, c-kit exon 11 deletions, in-
cluding codons 557 and/or 558, have been reported to 
predict a worse prognosis in GIST patients. However, it 
is dif cult to prove the correlation between genotype and 
tumor aggressiveness in the imatinib-adjuvant era. In 
this study, we evaluated the impact of c-kit mutational 
status on recurrence-free survival RFS  after resection 
of primary GIST. 
Methods : Clinical and pathological characteristics of 
89 GIST patients in our single institution study were ret-
rospectively analyzed. Tumors were categorized into 4 
subgroups based on their mutational locations ; 
A1 : mutated codons including neither 557 nor 558, A2 : 
either 557 or 558, B1 : only 557 and 558, B2 : both 557 
and 558. All of the patients underwent curative surgery, 
and none received adjuvant imatinib.
Results : Tumors originated from the stomach 
n=75 , small intestine n=10 , and colorectum n=4 .
The 2-year recurrence free survival rate for A1, A2, B1, 
B2, was 84.9%, 85.7%, 50%, 57%, respectively. Group 
B2 had a significantly worse RFS than groups A1 
p=0.0004  and A2 p=0.0014 . Multivariate analysis 
for RFS indicated that only the mutational subgroup was 
a signi cant prognostic factor p=0.03, HR=2.42 . 
Conclusions : C-kit mutations, including both 557 
and 558, affected the RFS of GIST patients after curative 
surgery, but those including either 557 or 558 did 
not. Our results indicate that the locations of c-kit mu-
tations are associated with PFS, and they may therefore 
affect the selection of candidates with GIST for adjuvant 
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imatinib.
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